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Sjogren’s syndrome (SS) is an autoimmune disease, among the most common ones, 
that targets mainly the exocrine glands as well as extra-glandular epithelial tissues. Their 
lymphocytic infiltration leads to manifestations from other organs (e.g., kidneys, lungs, 
liver, or thyroid), apart from sicca symptoms (xerostomia and keratoconjunctivitis). SS is 
more prevalent in women than in men (9:1). Moreover, p.SS patients are in increased risk 
to develop lymphoma. Certain autoantibodies (e.g., antibodies against ribonucleoprotein 
autoantigens Ro-SSA and La-SSB) are ultimate hallmarks for the disease. It was not 
known until recently that culture-independent techniques like next-generation sequencing 
(NGS) facilitate the study of the microbe communities in humans and scientists achieved 
to define the outlines of the microbiome contribution in health and disease. Researchers 
have started to investigate the alterations in diversity of the oral, ocular, or intestinal 
microbiota in SS. Recent studies indicate that dysbiosis may play a significant role in 
SS pathogenesis. At the same time, the cause or effect is not clear yet because the 
dysfunction of salivary glands induces alterations in oral and intestinal microbiome which 
is linked to worsen of symptoms and disease severity. If the human microbiome proves 
to play a key role in pathogenesis and manifestation of SS, the next step could be 
new and promising therapeutic approaches such as probiotics or prebiotics. This mini 
review focuses on the alterations of microbiome of SS patients, their connection with 
immune tolerance and new therapeutic strategies involving diet manipulation toward 
future personalized medicine.








•	 Diet	 interventions	and	supplementations	 for	SS	patients	need	 to	be	 thoroughly	examined	and	
researched	 to	 identify	novel	 therapies	and	prevention	measures	 in	 the	context	of	personalized	
medicine.
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inTRODUCTiOn
Sjogren’s	 syndrome	 (SS)	 is	 an	 autoimmune	 disease,	 among	
the	 most	 common	 ones,	 possibly	 as	 common	 as	 rheumatoid	




mouth).	 In	 addition,	 clinical	 symptoms	 could	 derive	 from	
autoimmune	invasion	(so	called	“autoimmune	epithelitis”)	(1)	
in	other	organs,	namely,	kidneys,	lungs,	etc.	It	is	a	heterogenous	
and	 multifactorial	 disease	 involving	 genetic,	 environmental,	
and	 hormonal	 parameters	 that	 may	 occur	 in	 any	 age	 with	 a	
male/female	ratio	1:10	(2).	SS	is	considered	a	benign	condition	
although	 is	 characterized	 by	 high	 incidence	 of	 lymphoma.	
Unfortunately,	it	is	a	disease	with	poor	diagnosis	and	undertreat-
ment	although	the	last	decades	a	lot	of	efforts	have	been	made	
by	 clinicians	 and	 researchers.	The	 gap	 in	 therapeutic	 options	
may	be	filled	by	 the	 recent	advances	 in	microbiome	research.	
Dysbiosis	has	already	been	a	suspect	for	SS’s	pathogenesis	like	









Several	 experimental	 approaches	demonstrated	 that	 there	 is	
a	link	between	gut	microbiota	alterations	and	disease	manifesta-
tions,	 severity	and	 treatment	 responsiveness.	For	example,	 it	 is	




Interventions	 targeting	 restoration	 of	 the	 microbiota	 shift	
using	 for	 example	 food	 supplements	 is	 currently	 under	 the	
microscope	to	elucidate	the	effects	on	clinical	status.	Prebiotics	
and	probiotics	are	considered	modern	strategies	for	gut	micro-
biota	 modulation,	 and	 we	 herewith	 provide	 a	 mini	 review	
focused	on	 the	 alterations	of	microbiome	of	 SS	patients,	 their	
microbiome–host	 interactions	 and	 novel	 treatments	 involving	
diet	manipulation	toward	future	personalized	medicine.
SHORT DiGeST in THe CURRenT  
STUDY OF SS
Sjogren’s	 syndrome	a	heterogenous	 and	multifactorial	disease	
involving	 genetic,	 environmental,	 and	 hormonal	 parameters	
that	may	 occur	 in	 any	 age	with	 a	male/female	 ratio	 1:10	 (2).	
When	SS	exists	solely	is	called	primary	SS	to	make	the	distinction	
from	 the	 situation	 of	 secondary	 SS	 when	 another	 autoim-
mune	 disease	 coexist	 or	 preexisted,	 namely,	 systematic	 lupus	
erythematosus	or	RA.	In	the	lymphocytic	infiltration	of	tissues,	










the	 release	 of	 adhesion	molecules	 and	 chemokines	 like	CD54/
ICAM-1	and	CD40	from	the	epithelial	cells	(7).	These	molecules	
recruit	 plasmacytoid	 dendritic	 cells	 and	 T-lymphocytes	 to	 the	
glands.	Dendritic	cells	release	high	levels	of	IFN-a	which	perpetu-
ates	the	recruitment	and	retention	of	the	T-lymphocytes,	mainly	















background	of	 SS.	 In	 addition,	 a	 lot	 of	 interest	 is	 accumulated	
toward	different	epigenetic	 factors	as	miRNA,	 long	non-coding	
RNA,	and	DNA	methylation	(13–15).
It	 is	 generally	 accepted	 that	 genetics	 in	 tandem	 with	 envi-
ronmental	 factors,	 especially	 viruses	 (chronic	 hepatitis	 virus,	
Epstein–Barr	 virus,	 etc.),	 provokes	 the	 initiation	 of	 a	 cataract	
that	leads	to	inflammation	and	autoimmunity	with	glandural	and	
extra	glandural	manifestations	(16).







on	 the	dark	 side	of	 the	moon.	 In	 the	dawn	of	 2017,	Birt	 et  al.	
in	 a	population-based	 study	which	 included	more	 than	10,000	
patients	with	pSS,	 suggested	 that	first	 line	drugs	are	 the	symp-
tomatic	and	immunosuppressive	ones	whereas	there	is	a	lack	of	
biologic	therapies	prescriptions	(19).	According	to	other	studies	
potential	 therapeutic	 interventions	 include	anti-BAFF	antibod-
ies	or	BAFF	antagonists	(e.g.,	Belimumab,	Atacicept,	Briobacept,	
etc.).	 In	 addition,	 anti-CD20	 and	 anti-CD22	 therapy	 results	 to	
B-cell	depletion	 leading	 to	 improvement	 in	SS	 symptoms	 (e.g.,	
rituximab),	methotrexate	as	an	immunosuppressive	drug	as	well	
and	 recently	 interleukin	 targeted	 treatment	 (e.g.,	 IL-6	 tocili-
zumab)	(16,	20–26).	Unfortunately,	all	these	options	still	require	
human	 trials	 to	 prove	 their	 effectiveness	 and	 especially	 in	 pSS	
patients.
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A new ACTOR On STAGe: THe HUMAn 
MiCROBiOMe
During	the	last	decades,	cutting-edge	together	with	the	expan-
sion	of	bioinformatics	 facilitated	 the	 scientists	 to	 elucidate	 the	
commensal,	 symbiotic	 and	 pathogenic	microbial	 communities	
of	 the	 human	 body.	 The	 next	 generation	 sequencing	 (NGS)	
methodologies	 encompass	 the	 16S	 ribosomal	 RNA	 (r	 RNA)	
gene	 sequencing	 and	 metagenomic	 shotgun	 sequencing	 (27).	
The	Human	Microbiome	Project	from	the	National	Institute	of	
Health	in	the	United	States	was	the	most	famous	initiative	that	











Most	 of	 the	microbes	 belong	 to	 four	major	 phyla:	 Firmicutes,	
Bacteroidetes,	Actinobacteria,	 and	 Proteobacteria	 (30–32)	 and	
actually	 Bacteroidetes	 along	 with	 Firmicutes	 represent	 more	




Europeans	 to	 three	enterotypes	with	 regard	 to	variation	of	gut	
microbiome	(31,	34).
There	 several	 factors	 which	 affect	 the	 numbers,	 composi-
tion,	 and	 diversity	 of	 intestine	 microbiota	 from	 newborn	 till	
the	 elderly	 such	 as	 gender,	 diet	 habits,	 smoking,	 vaccinations,	
infections,	 age,	 stress,	 etc.	During	 the	first	week	of	 its	 life,	 the	





origin	 (mother’s	 vagina	 versus	 skin	 origin)	 (33,	 35).	 Survey	
studies	depict	that	diversity	and	richness	augment	during	life	up	
to	adulthood	and	then	gradually	reduce	(36).	A	healthy	human	
intestine	microbiome	 is	 characterized	 by	 high	 diversity	 while	
any	 kind	 of	 loss	 of	 diversity	 may	 lead	 to	 dysbiosis,	 a	 critical	
condition	of	disproportion	between	commensal	and	pathogenic	
bacteria.	These	 commensals	 fill	 an	 important	niche	with	 their	
up	or	down	regulation	of	immune	response	and	by	maintaining	
a	 homeostatic	 environment.	As	 a	 result	 of	 these	 observations,	
there	 are	 numerous	 publications	 for	 the	 possible	 interaction	





interplay	 between	 pathogenesis,	 clinical	 manifestations,	 and	
disease	prognosis	with	the	microbiome	alterations.
Host	 immunity	 to	 pathogens	 is	 largely	 regulated	 by	 the	
commensal	 microbiota	 as	 numerous	 studies	 have	 shown.	 On	
the	 other	 hand,	 the	 microbiota	 implication	 in	 autoimmune	
response’s	regulation	is	still	a	matter	of	discussion	and	research	
(37).	 Recent	 findings	 describe	 the	 effect	 of	microbiome	 shifts	
toward	 the	 emergence	 of	 autoimmunity.	The	 introduction	 of	
high-throughput	methods	in	microbiome	analysis	like	sequenc-
ing	 of	 16S	 rRNA,	 next-generation	 sequencing	 (NGS),	 and	
metabolomics	offered	 the	opportunity	 for	 large	cohort	 studies	
which	 revealed	 that	 the	 role	 of	 microbiota	 in	 the	 context	 of	
autoimmunity	 could	 be	 “protective,	 neutral,	 or	 provocative”	
as	 Yurkovetskiy	 et  al.	 pointed	 out	 (38).	Microbiota	may	 have	
impact	on	autoimmunity	and	autoimmune	disease	development	
in	different	means.	Direct	effects	of	commensals	include	the	well	





might	 be	 another	part	 of	 a	 chain	 in	 this	 procedure	 (38).	Diet	
interventions	could	affect	target	organs	like	pancreas	or	neural	
tissue	 by	microbiota	 shifts	 or	 in	 a	 straight	 pathway.	 Relevant	









BiDiReCTiOnAL ReLATiOn BeTween 
MiCROBiOMe AnD SS
Having	 considered	 all	 the	 above	 it	 is	 more	 than	 obvious	 the	
accumulating	research	currently	focuses	on	the	contribution	of	
human	microbiome	 to	 systemic	 autoimmune	 diseases	 (SADs).	
Bacteria	 of	 the	 microbiome	 get	 in	 touch	 with	 the	 mucosal	
immune	system	and	after	various	 interactions	can	 lead	 to	dys-
biosis	with	local	inflammation	and	disruption	of	gut	barrier.	As	a	
cataract	numerous	consequences	might	occur,	for	instance,	pro-
inflammatory	 cytokines	 in	 systemic	 circulation,	distant	 impact	
of	inflammation	such	as	joints,	greater	antigen	exposure	with	the	
increase	of	autoantibody	production,	etc.	SADs	are	multifactorial	




in	 two	different	fields,	 harnessing	of	 immune	 response	 against	
beneficial	microbes	and	maintaining	the	wholeness	of	gut	barrier	





















FiGURe 1 | Microbiome and Sjogren’s syndrome.
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Another	 lymphocyte	 subpopulation	 that	 comprise	 a	 large	
number	is	the	T regulatory	(Treg)	cells.	Tregs	are	invaluable	for	










much	 attention	 especially	 for	 SS	 patients	 despite	 the	 fact	 that	
scientists	prove	 and	believe	 in	hereditary	 and	 familial	predis-
position	 and	EBV	association	 for	 the	disease	onset  along	with	
increased	production	of	type	I	IFN	(54–56).	It	is	quite	predictable	
the	 fact	 that	 the	main	body	of	 the	 related	 studies	 refers	 to	 the	
saliva	 alterations	 due	 to	 the	 attack	 of	 the	 salivary	 glands.	 As	
early	as	2003,	Almståhl	et al.	observed	 in	SS	patients’	saliva	an	
augmentation	 of	 Candida species	 and	 Streptococcus mutans	
whereas	 Fusobacterium nucleatum	 colony	 forming	 units	 were	
depleted	(57).	Moreover,	de	Paiva	et al.	found	additionally	high	




Faecalibacterium,	 Bacteroides,	 Parabacteroides,	 and	 Prevotella	




peptides	 produced	 from	 human	 commensals)	 could	 activate	
T cells	with	a	Ro60	receptor	and	leads	to	autoantibody	production	
(58).	Molecular	mimicry	 as	 a	 possible	mechanism	 for	 autoim-
munity	could	explain	the	microbiome–SS	connection	(58),	and	
deregulated	immune	response	fighting	the	normal	microbiome	
could	be	 considered	as	 a	potential	pathway	 in	SS	pathogenesis	
and	 disease	 perpetuation.	 Regretfully,	 just	 hints	 and	 indirect	
evidences	are	the	only	elements	in	this	puzzle	up	to	now.
It	 is	 generally	 accepted	 the	 pathophysiological	 role	 of	 auto-
reactive	B  cells	 and	Th17 cells	 in	 SS	 and	 the	direct	or	 indirect	
implication	of	the	human	microbiome.
Th17	cells	are	present	in	salivary	glands	of	SS	patients	and	in	
peripheral	 blood	 as	well.	 So	 it	 could	 be	 a	 solid	 hypothesis	 the	
increase	of	this	population	due	to	dysbiosis	leads	to	entering	the	
circulation	 and	 reach	 the	 exocrine	 glands.	 Unfortunately,	 it	 is	
still	unclear	 if	 the	origin	of	 the	Th17 cells	 is	 lamina	propria	of	
the	gut	and	the	pattern	that	gut	immunity	triggers	autoimmune	
procedures	at	distal	sites	(i.e.,	salivary	glands)	(42).
MiCROBiOMe SHiFTS AnD FUTURe 










leads	 to	 deregulation	 of	 immune	 and	 metabolic	 homeostasis,	






of	 the	 disturbed	 gut–barrier	 encompass	 generally	 probiotics,	
prebiotics,	 dietary	 fiber,	 and	 fecal	 microbiota	 transplantation	
depending	on	the	disease.
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Probiotics	are	live	microorganisms	which	when	administered	
in	 adequate	 amounts	 confer	 a	 health	 benefit	 on	 the	 host	 (61).	
Probiotic	microorganisms	 include	 principally	 bacteria	 that	
produce	lactic	acid	as	Lactobacillus	and	Bifidobacterium	genera	
(LAB).	 Their	 use	 is	 mainly	 to	 restore	 the	 microbiota	 imbal-
ance	by	different	mechanisms	that	are	still	under	research	(62)	
even	 though	 there	 are	 plenty	 of	 studies	 that	 demonstrate	 the	
beneficial	 effect	on	allergic	diseases	 (e.g.,	 asthma	and	eczema),	
obesity,	metabolic	syndrome,	gastrointestinal	disorders,	etc.	(60).	
Prebiotics	 are	 non-digestible	 fermentable	 oligosaccharides	 that	
could	alter	 the	composition	and/or	 the	 functionality	of	 the	gut	
flora	 and	 contribute	 to	 the	 increase	 of	 the	 beneficial	 bacteria,	
namely,	Lactobacilli	and	Bifidobacteria	(36,	63,	64).	In	the	same	
manner,	 a	 combination	 of	 pre-	 and	 probiotics	 (symbiotic)	 has	
been	used	(65).
Currently,	researchers	spark	interest	in	the	therapeutic	capa-
bility	 of	 probiotics	 and	 prebiotics	 based	 approaches	 regarding	
autoimmune	diseases.	This	strategy	might	represent	a	more	
natural	 way	 to	 master	 the	 autoimmune	 response	 by	 avoiding	
any	 side	 effects	 of	 immunosuppressive	 drugs.	The	most	 recent	
studies	 focus	 on	 the	 effect	 of	 functional	 food	 (prebiotics	 and	
probiotics)	on	Treg	cells	concerning	autoimmune	disorders	(66).	
Natural	 Treg	 cells	 population	 represents	 the	 cornerstone	 for	
the	 peripheral	 tolerance,	 playing	 a	 crucial	 role	 to	 suppress	 the	
autoreactive	 T-cells	 which	 have	 surpassed	 thymus	 supervision	
and	cancel	any	autoimmune	response.	Any	kind	of	 inadequacy	
of	these	cells	as	regards	the	number	or	activity	seems	to	be	cor-
related	with	different	 autoimmune	disorders,	 for	 instance,	der-
matomyositis	(67),	systemic	lupus	erythematosus	(68),	or	vitiligo	
(69).	Konieczna	et al.	in	2012	revealed	that	certain	probiotics	can	
promote	 the	 induction	 of	Tregs	 in	 patients	with	 inflammatory	
disease	(70).	This	induction	could	restore	the	imbalance	between	
Tregs	 and	 effector	 CD8+	 CD4+	 Tcells	 (in	 greater	 number	 in	
autoimmunity)	 resulting	 in	 immune	 homeostasis	 (decrease	 of	
pro-inflammatory	 factors,	 augmentation	 of	 anti-inflammatory	








strains	 in	 experimental	 colitis,	 T1DM	 and	 IBD.	These	 results	
could	be	valuable	lessons	for	future	studies	in	animal	and	humans	
regarding	 SS	 and	 the	 shaping	 of	 the	 microbiota	 to	 suppress	
autoimmunity.	Given	the	crucial	role	of	the	benefic	bacteria	and	
the	 possible	 diet	 interventions	 using	 probiotics	 and	 prebiotics,	
SS	 patients	 could	 ameliorate	 disease	 severity	 and	 prediction.	
The	paucity	of	studies	concerning	specifically	this	entity,	either	
animal	or	human	studies	reveals	the	magnitude	of	the	problem.	




Sjogren’s	 syndrome	 as	 a	 common,	 multifactorial	 autoimmune	
disorder	 remains	 till	 now	 mostly	 underdiagnosed	 and	 under-
treated.	At	the	same	time	as	the	latest	breakthroughs	in	culture-
independent	techniques	of	studying	human	microbiome	revealed	
its	 possible	 connection	 with	 SS	 pathogenesis,	 onset,	 severity,	
and	 treatment,	 scientific	community	 sparked	off	a	new	field	of	
interest.	Having	considered	pioneer	research	as	regards	autoim-
munity	 and	microbiota	 in	 general	 and	 the	profound	 contribu-
tion	of	dysbiosis,	 future	efforts	possibly	would	be	focused	first,	
on	 the	 determination	 whether	 the	 reduced/altered	 microbial	
diversity	 is	causal.	Second,	 it	 seems	essential	 to	define	 the	pre-




microbiota	 with	 the	 positive,	 negative	 and	 neutral	 bacteria	 in	
tandem	with	their	resilience	and	stability	(71)	on	one	hand	and	
specific	markers	 for	 the	 efficiency	 of	 the	 interventions	 on	 the	
other,	 would	 give	 prominence	 and	 real	 value	 to	 the	 outcome	
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